Slingshot members are tracking this event:

MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo Phase II Clinical Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
MolecularMD Community voting in process
D4S.F Community voting in process

Additional Information

Additional Relevant Details In collaboration with Daiichi Sankyo, MolecularMD has validated a clinical trial assay that will be used to enrich the patient population for a Phase II clinical trial which is commencing in Europe. MolecularMD has completed the CE registration with the European authorities to ensure future access as an assay, which is to be used for patient selection into the trial.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ce Mark, Phase Ii